Spruce Biosciences, Inc.SPRB

Spruce Biosciences is a pre-revenue biotech chasing Sanfilippo Syndrome Type B with a therapy called TA-ERT, yet its latest SEC filing shows it has not generated a single dollar of revenue as of December 31, 2025.

The company’s glossy patient-facing website frames its mission around “meaningful therapies” delivered with “science, empathy, and patient voices,” while its 10-Q for the quarter ended March 31, 2026 reveals an operating loss of $12.0 million and a burn of $8.7 million in operating cash during the period.

On the financing side, Spruce has agreed to pay Jefferies a 3% commission on any equity issued under a sales agreement and also carries a $25.5 million obligation to BioMarin tied to potential product sales milestones, giving new meaning to the phrase “paying for the privilege of waiting.” The company’s $54.1 million cash pile is comforting only until you realise it is being depleted each quarter while the therapy remains in development.

For those tracking the gap between narrative and numbers, Spruce’s diluted share count stood at 1.4 million as of March 31, 2026, with R&D expense of $7.6 million in the quarter, while capital expenditure amounted to just $10,000-a figure that suggests the company is renting rather than building anything resembling an operational footprint.

Spruce’s product website continues to collect user data via third-party advertising and analytics partners, a reminder that the company is monetising attention even as it awaits regulatory approvals or commercial sales. Meanwhile, the CEO, Javier Szwarcberg, MD, MPH, remains active in filings, with a July 9, 2026 Form 4 showing continued insider activity.

The central tension is simple: the company’s market story outruns its filing story. Until TA-ERT delivers clinical validation or revenue, the numbers remain stubbornly zero, and the board’s reliance on Jefferies commissions and BioMarin milestones looks less like strategic financing and more like a high-wire act with no net.